Evidence map›Paper›PMID 23668478›Full record

Trial reportDiabetes, obesity & metabolism2013

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.

H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List

5 registry-linked trialsOpen access · hybridAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 374 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
374citing papers in PubMed, 14 pooled it
26.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02113241 phase2 / phase3completedstarted 2014, after this paper: background citation

Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Ran2014Enrolled24Registered outcomes24Posted comparisons48ConditionsMetabolic Syndrome XArmsdapagliflozin, Placebo
PMID 24463448PMID 23906445PMID 22238392PMID 24105299PMID 24130972PMID 23910664PMID 23210765PMID 23194084PMID 22701099PMID 22446170PMID 20566676PMID 20518806other papers from this trial
Open the trial in the graph
NCT02887677 phase4terminatedstarted 2016, after this paper: background citation

A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes

Ran2016Enrolled85Registered outcomes9Posted comparisons0ConditionsDiabetes MellitusArmsdapagliflozin, Placebo
PMID 22411919PMID 24919526PMID 24745924PMID 22673021PMID 8366922PMID 26623980PMID 25322847PMID 25319601PMID 25230708PMID 25126392PMID 25054271PMID 24989141other papers from this trial
Open the trial in the graph
NCT03658031 phase3unknown statusstarted 2019, after this paper: background citation

Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

Ran2019Enrolled576Registered outcomes1Posted comparisons0ConditionsCVD, Myocardial Infarction, Prediabetes, T2DM (Type 2 Diabetes Mellitus)ArmsDapagliflozin 10mg
PMID 28096223PMID 25425451PMID 28428225PMID 27679584PMID 27814267PMID 24631482PMID 19490820PMID 17315136PMID 25739882PMID 28615237PMID 29227578PMID 16644654other papers from this trial
Open the trial in the graph
NCT03917758 naunknown statusstarted 2018, after this paper: background citation

Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study

Ran2018Enrolled30Registered outcomes24Posted comparisons0ConditionsArterial Hypertension, Body Weight Changes, Diabetes Mellitus, Type 2ArmsSGLT2 inhibitor
PMID 27822054PMID 23735727PMID 23624546PMID 27802313PMID 26378978PMID 26321369PMID 26161452PMID 24334175other papers from this trial
Open the trial in the graph
NCT07174687 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorWashington University School of MedicineRan2025 to 2028Enrolled70ConditionsRetinal Degeneration, Retinal Diseases, Eye Diseases, Geographic AtrophyArmsDapagliflozin, Matching Placebo
3 · Its place in the literature

Who cites it

374 citing papers in PubMed, 14 syntheses or guidelines pooled it, 814 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Canagliflozin and iron metabolism in the CREDENCE trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025 · on this map
    Trial
  19. Trial
  20. Trial

314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

H J Lambers HeerspinkDepartment of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. h.j.lambers.heerspink@umcg.nl
D de Zeeuw
L Wie
B Leslie
J List
Bristol-Myers Squibb (Sweden) · SEBristol-Myers Squibb (France) · FRUniversity Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsSodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion. To investigate whether the parallel occurring sodium loss would have diuretic-like physiologic effects, we compared dapagliflozin and hydrochlorothiazide (HCTZ) effects on 24-h blood pressure (BP), body weight, plasma volume and glomerular filtration rate (GFR).

methodsIn this randomized, placebo-controlled, double-blind trial, 75 subjects with type 2 diabetes were assigned placebo, dapagliflozin 10 mg/day, or HCTZ 25 mg/day. Changes from baseline BP, body weight, plasma volume and GFR were assessed after 12 weeks of treatment.

resultsSubjects' mean age was 56 years, type 2 diabetes mellitus (T2DM) duration 6.3 years, and haemoglobin A1c (HbA1c) 7.5%. Treatment with placebo, dapagliflozin or HCTZ resulted in changes from baseline in 24-h ambulatory mean systolic blood pressure (SBP) of -0.9 (95%CI -4.2, +2.4), -3.3 (95%CI -6.8, +0.2), and -6.6 (95%CI -9.9, -3.2) mmHg, respectively at week 12, adjusted for baseline SBP. Body weight decreased with dapagliflozin and HCTZ. In a sub-study plasma volume appeared to decrease with dapagliflozin but did not change with placebo or HCTZ treatment. Dapagliflozin induced a greater reduction in GFR (-10.8%; 95%CI -14.6, -6.7) relative to placebo (-2.9%; 95% CI -6.9, +1.2) or HCTZ (-3.4%; 95%CI -7.3, +0.6).

conclusionsDapagliflozin-induced SGLT2 inhibition for 12 weeks is associated with reductions in 24-h BP, body weight, GFR and possibly plasma volume. Cumulatively, these effects suggest that dapagliflozin may have a diuretic-like capacity to lower BP in addition to beneficial effects on glycaemic control.

Indexed as

Sodium-Glucose Transporter 2 InhibitorsAdolescentAdultAgedBenzhydryl CompoundsBlood GlucoseBlood PressureDiabetes Mellitus, Type 2DiureticsDouble-Blind MethodDrug Therapy, CombinationFemaleGlucosidesHumansHydrochlorothiazideHypoglycemic AgentsBenzhydryl CompoundsBlood GlucosedapagliflozinDiureticsGlucosidesHydrochlorothiazideHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorsblood pressuredapagliflozinHbA1crenal functiontype 2 diabetes

Identifiers

PMID23668478
PMCPMC3906841
OpenAlexW2153839551

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.